Agouron Viracept shows 2.3 to 2.5 log reduction in combination with AZT, 3TC.
Executive Summary
AGOURON VIRACEPT SHOWS 2.3 TO 2.5 LOG REDUCTION IN COMBINATION with Glaxo Wellcome's Retrovir (AZT) and Epivir (3TC, lamivudine), according to results from pivotal Phase II/III trials of Viracept (nelfinavir mesylate) presented Jan. 24 at the 4th Conference on Retroviruses and Opportunistic Infections in Washington, D.C.